文献速递先天性心脏病外科

不平衡型房室间隔缺损单心室姑息治疗的长期结局:Fontan存活者优于既往认知

Long-term outcomes of single-ventricle palliation for unbalanced atrioventricular septal defects: Fontan survivors do better than previously thought.
PubMed 文献 · J Thorac Cardiovasc Surg · 2016-09-24

该单中心回顾性研究纳入1976至2016年139例因不平衡型房室间隔缺损接受单心室姑息治疗的患儿,分析各阶段死亡率及长期生存。结果显示25年总体生存率57.8%,而完成Fontan者25年生存率达82.4%,主动脉闭锁和主动脉弓发育不良是死亡或移植的危险因素。

要点

  • uAVSD单心室姑息治疗25年总体生存率57.8%,但Fontan完成者达82.4%。
  • 主动脉闭锁(HR 5.3)和主动脉弓发育不良(HR 2.5)与死亡或移植风险相关。
  • 31.7%患者需房室瓣手术,其中31.8%需再次手术。

核心结论

  • uAVSD单心室姑息治疗总体死亡率较高,25年生存率低于60%,但完成Fontan者长期生存优于既往报道。

研究设计与样本

  • 单中心回顾性队列研究,纳入1976至2016年139例接受单心室姑息治疗的不平衡型房室间隔缺损患儿,数据来自病历及与全科医生和心脏病专家的通信。

主要发现

  • 新生儿姑息手术占83.5%(116/139),早期死亡率11.2%(13/116)。
  • 二期姑息手术94例,早期死亡率6.4%(6/94);Fontan完成80例(57.6%),早期死亡率3.8%(3/80)。
  • 一期至二期阶段间死亡率11.7%(12/103),二期至Fontan阶段间死亡率17.0%(15/88)。
  • 总体生存率5年66.5%(95%CI 57.9%-73.9%)、15年64.4%(95%CI 55.5%-72.0%)、25年57.8%(95%CI 47.5%-66.8%)。
  • Fontan术后生存率5年94.9%(95%CI 86.9%-98.0%)、15年92.0%(95%CI 80.6%-96.8%)、25年82.4%(95%CI 61.5%-92.6%)。

关键数值与推荐

  • 31.7%(44/139)患者需房室瓣手术,其中31.8%(14/44)需再次手术。

临床怎么用

  • 咨询时应告知uAVSD单心室姑息治疗各阶段死亡风险及阶段间死亡率,但完成Fontan者长期预后较好。
  • 对合并主动脉闭锁或主动脉弓发育不良者应识别为高危人群并加强管理。
  • 需关注房室瓣反流及再次手术风险,随访中评估房室瓣功能。

局限性

  • 单中心回顾性研究,跨1976至2016年,诊疗策略可能随时间变化。
  • 部分数据来自通信随访,可能存在信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Single-ventricle palliation (SVP) for children with unbalanced atrioventricular septal defect (uAVSD) is thought to carry a poor prognosis, but limited data have been reported. METHODS: We performed a retrospective review of children with uAVSD who underwent SVP at a single institution. Data were obtained from medical records and correspondence with general practitioners and cardiologists. RESULTS: Between 1976 and 2016, a total of 139 patients underwent SVP for uAVSD. A neonatal palliative procedure was performed in 83.5% of these patients (116 of 139), and early mortality occurred in 11.2% (13 of 116). Ninety-four patients underwent stage II palliation, with an early mortality of 6.4% (6 of 94). Eighty patients (57.6%) underwent Fontan completion, with an early mortality of 3.8% (3 of 80). Interstage mortality was 11.7% (12 of 103) between stages I and II and 17.0% (15 of 88) between stage II and Fontan. Long-term survival was 66.5% (95% confidence interval [CI], 57.9%-73.9%) at 5 years, 64.4% (95% CI, 55.5%-72.0%) at 15 years, and 57.8% (95% CI, 47.5%-66.8%) at 25 years. Survival post-Fontan was 94.9% (95% CI, 86.9%-98.0%) at 5 years, 92.0% (95% CI, 80.6%-96.8%) at 15 years, and 82.4% (95% CI, 61.5%-92.6%) at 25 years. Risk factors associated with death or transplantation were aortic atresia (hazard ratio [HR], 5.3; P = .03) and hypoplastic aortic arch (HR, 2.5; P = .02). Atrioventricular valve operations were required in 31.7% of the patients (44 of 139), with 31.8% of them (14 of 44) requiring a further operation. CONCLUSIONS: Children undergoing SVP for uAVSD have substantial mortality, with <60% survival at 25 years. However, survival of children who achieve Fontan completion is better than has been reported previously.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Buratto E, Ye XT, King G, et al. Long-term outcomes of single-ventricle palliation for unbalanced atrioventricular septal defects: Fontan survivors do better than previously thought. J Thorac Cardiovasc Surg. 2016. PMID: 28029339. doi:10.1016/j.jtcvs.2016.09.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。